36 terminated. 36 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Terminated 36 |
| Phase 2 | 8 | Terminated 8 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) Ublituximab, Umbralisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 277 | 2019-05-16 | 2024-04-19 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia Obinutuzumab, Ublituximab, TGR-1202 - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | TG Therapeutics, Inc. | 603 | 2015-11-19 | 2024-12-13 |
| Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 57 | 2015-04-21 | 2018-11-19 |
| Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 311 | 2014-02-05 | 2018-11-19 |
| Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Blinatumomab, Standard of Care Chemotherapy - Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Amgen | 405 | 2014-01-03 | 2024-03-05 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Placebo, Rituximab, Idelalisib - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | Gilead Sciences | 295 | 2013-01-16 | 2018-11-16 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | Gilead Sciences | 475 | 2013-01-02 | 2018-11-16 |
| Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 261 | 2012-12-04 | 2019-08-14 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 3 | Terminated | Hospital Israelita Albert Einstein | 3 | 2012-12-01 | 2017-03-03 |
| Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) Idelalisib - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | Gilead Sciences | 161 | 2012-10-03 | 2019-08-20 |
| A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI) - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 26 | 2012-03-01 | 2021-09-09 |
| The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Cholecalciferol, oleum neutralicum - Chronic Lymphoid Leukemia | Phase 3 | Terminated | Semmelweis University | 31 | 2012-01-01 | 2020-07-16 |
| Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Ofatumumab, Observation - Leukaemia, Lymphocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 480 | 2010-05-06 | 2019-07-30 |
| PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia DepoCyte - Acute Lymphoblastic Leukemia | Phase 3 | Terminated | PETHEMA Foundation | 7 | 2009-09-01 | 2015-05-08 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Kiadis Pharma | 40 | 2009-08-01 | 2021-06-14 |
| Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia chlorambucil, tablets, ofatumumab (GSK1841157) infusion - Leukaemia, Lymphocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 447 | 2008-12-22 | 2019-06-25 |
Showing 20 of 36. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Leukemia (10) · Lymphoma (8) · Lymphoma, Follicular (8) · Lymphoma, B-Cell, Marginal Zone (7) · Myelodysplastic Syndromes (7) · Graft vs Host Disease (5) · Leukemia, Myeloid, Acute (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Leukemia, B-Cell (4) · Multiple Myeloma (4)
Hematologic Diseases (36) · Hemic and Lymphatic Diseases (36) · Immune System Diseases (36) · Immunoproliferative Disorders (36) · Lymphatic Diseases (36) · Lymphoproliferative Disorders (36) · Neoplasms by Histologic Type (36) · Neoplasms (34) · Leukemia (26) · Disease Attributes (21) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Chronic Disease (20) · Leukemia, B-Cell (16)
Cyclophosphamide (7) · idelalisib (6) · Methotrexate (5) · Rituximab (4) · Bendamustine Hydrochloride (3) · Chlorambucil (3) · Etoposide (3) · Vincristine (3) · ofatumumab (3) · ublituximab (3) · umbralisib (3) · Asparaginase (2) · Busulfan (2) · Cyclosporine (2) · Doxorubicin (2)
Gilead Sciences (6) · TG Therapeutics, Inc. (3) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Kiadis Pharma (2) · M.D. Anderson Cancer Center (2) · Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Amgen (1) · Baxalta now part of Shire (1) · Children's Hospital of Philadelphia (1) · Dana-Farber Cancer Institute (1) · German CLL Study Group (1) · Hospital Israelita Albert Einstein (1) · Institut de Recherches Internationales Servier (1) · Martin, Paul (1)
United States (29) · Canada (13) · Spain (12) · United Kingdom (12) · France (11) · Italy (11) · Belgium (10) · Poland (10) · Australia (9) · Germany (7) · Israel (7) · Czechia (6) · Netherlands (6) · Russia (6) · Sweden (6)
Andrea Velardi, MD (1) · Ching-Hon Pui, MD (1) · Daniel J. DeAngelo, MD, PhD (1) · Denis Claude Roy, Prof MD (1) · Denis-Claude Roy, MD (1) · Istvan Takacs, MD, PhD (1) · John C. Byrd, MD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Julie M. Vose, MD (1) · Katy Rezvani, MD PhD (1) · Khanh Vu, MD (1) · Marcos de Lima, MD (1)
PMID 15226337, PMID 15247354, PMID 19270260, PMID 20850381, PMID 22658895, PMID 25103870, PMID 25882396, PMID 28257752, PMID 30916608, PMID 30995176, PMID 32289160, PMID 32599655, PMID 33026184, PMID 33054084, PMID 33542479, PMID 33683917, PMID 34161631, PMID 35622074, PMID 41074700
2015 (1), 2016 (1), P30CA036727 (1), P30CA069533 (1), U10CA031946 (1)